Myogen Inc.'s lead product, enoximone, missed statistical significance in the primary endpoint of a Phase III trial to support an ongoing pair of other, pivotal Phase III studies - but the company said success in secondary endpoints means the study's objective was achieved. (BioWorld Today) Read More